miércoles, 7 de octubre de 2026
BuscarExplore
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 22, 2026

The Best Vanguard ETF to Buy and Hold for the Next Decade (It Has Significant AI Exposure)

View original at nasdaq.com
The Best Vanguard ETF to Buy and Hold for the Next Decade (It Has Significant AI Exposure) Key Points The Vanguard S&P 500 ETF carries an expense ratio of just 0.03%…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • VOO's top five holdings — Nvidia, Apple, Microsoft, Amazon, and Alphabet — account for roughly a quarter of the entire fund

    60% confidence
  • Investors poured well over $100 billion of new money into VOO in 2025 alone

    60% confidence
  • Nvidia supplies the chips powering much of the AI build-out and is VOO's biggest holding

    60% confidence
  • Apple remains the world's largest consumer hardware company

    60% confidence
  • The Vanguard S&P 500 ETF is the best Vanguard ETF to own for the next decade due to its extremely low fee and deep exposure to America's most dominant companies

    60% confidence
  • In the S&P 500's more than 50-year history, negative 10-year stretches have been rare

    60% confidence
  • VOO's expense ratio is 0.03%, while the average fund in its category charges around 0.67%

    60% confidence
  • VOO's heavy tilt toward U.S. mega-cap tech means it could come under pressure if the AI build-out disappoints or if rising rates and stretched valuations weigh on growth stocks

    60% confidence
  • Amazon Web Services is the world's largest cloud infrastructure provider

    60% confidence
  • VOO net assets are approaching $1 trillion, a level no other ETF has ever reached

    60% confidence
  • The S&P 500 has produced an average annual total return of about 10.3% with dividends reinvested since 1957

    60% confidence
  • A $1,000 investment in Netflix at the time of Stock Advisor's December 17, 2004 recommendation would be worth $481,589 as of May 22, 2026

    60% confidence
  • Information technology accounts for roughly 34% of the VOO fund, with financial services and communication services rounding out the three largest sectors

    60% confidence
  • A $1,000 investment in Nvidia at the time of Stock Advisor's April 15, 2005 recommendation would be worth $1,345,714 as of May 22, 2026

    60% confidence
  • The SPDR S&P 500 ETF Trust (SPY) charges about 0.09%, triple the cost of VOO

    60% confidence
  • VOO's top 10 holdings combined add up to more than 36% of total assets

    60% confidence
  • The S&P 500's trailing 10-year annualized return is roughly 15%

    60% confidence
  • Dollar-cost averaging may be the smartest approach for investors looking to hedge against the risk of buying VOO at the wrong time

    60% confidence
  • Stock Advisor's total average return is 993%, versus 208% for the S&P 500

    60% confidence
  • Vanguard is essentially owned by its funds, which in turn are owned by its investors, aligning incentives toward continually lowering costs

    60% confidence
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
The Best Vanguard ETF to Buy and Hold for the Next Decade (It Has Significant AI Exposure) — Source | Via News | es.VIA.NEWS